This is a very good idea.

He found that the data was not submitted for almost 60% of papers, and that data for 75% of papers were not in a format suitable for replication.

I recently needed large tables of data from 4 different publications. The data was provided... as PDFs. I had to copy thousands of lines of data out from the PDFs by hand. Journals prefer PDF format because it's device-independent.

It's questionable how much good science can do, though, when we're already so far behind in applying biotech research in the clinic. My cousin died last week just after her 40th birthday, partly from a bacterial infection. The hospital couldn't identify the bacteria because they're only allowed to use FDA-approved diagnostic tests. The approved tests involve taking a sample, culturing it, and using an immunoassay to test for proteins of one particular bacteria. This takes days, costs about $400 per test, tests only for one particular species or strain of bacteria per test, has only a small number of possible tests available, and has a high false negative rate. It was a reasonable approach 25 years ago.

Where I work, we take a sample, amplify it via PCR (choosing the primers is a tricky but solved problem), and sequence everything. We identify everything, hundreds of bacterial species, whether they can be cultured or not, in a single quick test. If you don't have a sequencer, you could use a 96-well plate to test against at least 96 bacterial groups, or a DNA hybridization microarray to test against every known bacterial species, for $200-$500. The FDA has no process for approving these tests other than to go through a separate validation process for every species being tested for, and no way to add the DNA of newly-discovered species to a microarray that's been approved.